Ignite Creation Date:
2024-05-05 @ 4:44 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00305461
Status:
COMPLETED
Last Update Posted:
2016-12-05
First Post:
2006-03-21
Brief Title:
Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma 21 to 65 y BY9010AR-101
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Pilot Study on the Impact of Two Different Doses of Ciclesonide 160 mcgDay and 320 mcgDay Administered in the Evening on Quality of Life in Patients With Moderate Persistent Asthma
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the study is to compare the effect of ciclesonide on quality of life pulmonary function and time to first exacerbation in patients with moderate persistent asthma Ciclesonide will be administered once daily in the evening at two dose levels The study duration consists of a baseline period 2 weeks and a treatment period 8 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None